Breaking Finance News

JP Morgan Cazenove issued a report on GlaxoSmithKline PLC (LON:GSK), upping its target price to 1,667.00GBX today

GlaxoSmithKline PLC (LON:GSK) had its target price raised to 1,667.00GBX by JP Morgan Cazenove in a report released Wednesday October 19, 2016. The new target price indicates remote upside the company's previous stock price.

Having a price of 1,672.50GBX, GlaxoSmithKline PLC (LON:GSK) traded 0.12% higher on the day. With the last stock price up 6.32% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. GSK has recorded a 50-day average of 1,651.49GBX and a two hundred day average of 1,567.94GBX. 8,058,650 shares of GSK traded hands, up from an average trading volume of 7,563,720

Recent Performance Chart

GlaxoSmithKline PLC (LON:GSK)

GlaxoSmithKline PLC has 52 week low of 1,277.25GBX and a 52 week high of 1,745.56GBX with a PE ratio of 2,778.33 and has a market capitalization of 0 GBX.

In addition to JP Morgan Cazenove reporting its stock price target, a total of 24 analysts have released a research note on GSK. The one year target is 1,577.33GBX with three analysts rating the company a strong buy, six analysts rating the company a buy, seventeen analysts rating the company a hold, two analysts rating the company a underperform, and lastly zero analysts rating the company a sell.

More About GlaxoSmithKline PLC (LON:GSK)

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.